{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:08:49Z","timestamp":1792012129324,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>We report a rare case of ovarian hyperstimulation syndrome (OHSS) in a 28-year-old woman with breast cancer and with a history of polycystic ovary syndrome (PCOS) despite treatment with letrozole and gonadotropin-releasing hormone agonist (GnRH-a) triggering in a GnRH antagonist (GnRH-ant) protocol without the administration of any human chorionic gonadotropin (hCG) for luteal-phase support. The patient, who underwent controlled ovarian syndrome (COS)-oocyte cryopreservation before chemotherapy, required hospitalization. Complete recovery was achieved after treatment with volume expanders, human albumin, and cabergoline. Based on our case and literature review, it is possible to establish that estradiol (E<jats:sub>2<\/jats:sub>) modulation with letrozole and GnRH-a triggering does not eliminate the risk of OHSS. Furthermore, it is advisable to postpone GnRH-a <jats:italic>depot<\/jats:italic> to minimize the risk of OHSS after the suspension of letrozole, following menstruation or at least 7\u20138 days after triggering. It would be desirable to identify high-risk patients, also on a genetic basis, in order to avoid delays in oncologic treatments that could strongly impact life expectancy.<\/jats:p>","DOI":"10.3389\/frph.2021.704153","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:05:55Z","timestamp":1625547955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Severe Ovarian Hyperstimulation Syndrome in a Woman With Breast Cancer Under Letrozole Triggered With GnRH Agonist: A Case Report and Review of the Literature"],"prefix":"10.3389","volume":"3","author":[{"given":"Giuseppe Gabriele","family":"Iorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika Ylenia","family":"Rovetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Vallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cariati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bagnulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"La Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Alviggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","author":"Pfeifer","year":"2016","journal-title":"Fertil Steril."},{"key":"B2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0015-0282(00)00670-1","article-title":"Role of vascular endothelial growth factor in ovarian physiology and pathology","volume":"74","author":"Geva","year":"2000","journal-title":"Fertil Steril."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1210\/jcem.80.6.7775647","article-title":"Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor\/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome","volume":"80","author":"Neulen","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.fertnstert.2009.05.092","article-title":"Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome","volume":"94","author":"Luke","year":"2010","journal-title":"Fertil Steril."},{"key":"B5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/humrep\/dep436","article-title":"Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)","volume":"25","author":"Lainas","year":"2010","journal-title":"Hum Reprod."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum Reprod."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.fertnstert.2014.01.019","article-title":"Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and \u201cfreeze-all\u201d approach in GnRH antagonist protocol","volume":"101","author":"Fatemi","year":"2014","journal-title":"Fertil Steril."},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/09513590.2018.1548591","article-title":"Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome","volume":"35","author":"Friedler","year":"2019","journal-title":"Gynecol Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.rbmo.2014.07.022","article-title":"Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases","volume":"29","author":"Gurbuz","year":"2014","journal-title":"Reprod Biomed Online."},{"key":"B10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.rbmo.2014.05.012","article-title":"GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'","volume":"29","author":"Ling","year":"2014","journal-title":"Reprod Biomed Online."},{"key":"B11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4103\/0974-1208.170415","article-title":"Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis","volume":"8","author":"Mahajan","year":"2015","journal-title":"J Hum Reprod Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10815-017-0960-0","article-title":"Ovarian hyperstimulation syndrome following GnRH agonist trigger\u2014think ectopic","volume":"34","author":"Orvieto","year":"2017","journal-title":"J Assist Reprod Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10815-015-0498-y","article-title":"Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and \u201cfreeze-all\u201d: in-depth analysis of genetic predisposition","volume":"32","author":"Santos-Ribeiro","year":"2015","journal-title":"J Assist Reprod Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e233379","DOI":"10.1136\/bcr-2019-233379","article-title":"Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle","volume":"13","author":"Singh","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1023\/B:JARG.0000027016.65749.ad","article-title":"Use of stimulated serum estradiol measurements for the prediction of hyper-response to ovarian stimulation in in vitro fertilization (IVF)","volume":"21","author":"Hendriks","year":"2004","journal-title":"J Assist Reprod Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/humrep\/dem254","article-title":"Serum anti-M\u00fcllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles","volume":"23","author":"Lee","year":"2008","journal-title":"Hum Reprod."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","article-title":"Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation","volume":"23","author":"Oktay","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3109\/00016340903287482","article-title":"Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization","volume":"88","author":"Kahnberg","year":"2009","journal-title":"Acta Obstet Gynecol Scand."},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B20","first-page":"3134","article-title":"High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients","volume":"21","author":"Alviggi","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10815-014-0248-6","article-title":"Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience","volume":"31","author":"Reddy","year":"2014","journal-title":"J Assist Reprod Genet."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008046.pub4","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","author":"Youssef","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10815-011-9676-8","article-title":"Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report","volume":"29","author":"Kim","year":"2012","journal-title":"J Assist Reprod Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil Steril."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1073\/pnas.1318978111","article-title":"Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression","volume":"111","author":"Sen","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","first-page":"869","article-title":"Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome","volume":"45","author":"Wang","year":"2013","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101815","DOI":"10.1016\/j.jogoh.2020.101815","article-title":"Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation?","volume":"17","author":"Marin","year":"2020","journal-title":"Reflections on a critical case of ovarian hyperstimulation syndrome. J Gynecol Obstet Hum Reprod."},{"key":"B28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10815-020-02051-7","article-title":"Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients","volume":"38","author":"Christ","year":"2021","journal-title":"J Assist Reprod Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09513590.2016.1266325","article-title":"Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols","volume":"33","author":"Lawrenz","year":"2017","journal-title":"Gynecol Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.rbmo.2017.09.014","article-title":"GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?","volume":"36","author":"Lawrenz","year":"2018","journal-title":"Reprod Biomed Online."},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10815-018-1372-5","article-title":"Rare genetic variants potentially involved in ovarian hyperstimulation syndrome","volume":"36","author":"Stouffs","year":"2019","journal-title":"J Assist Reprod Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s10815-020-01941-0","article-title":"Rare genetic variants suggest dysregulation of signaling pathways in low- and high-risk patients developing severe ovarian hyperstimulation syndrome","volume":"37","author":"Borgwardt","year":"2020","journal-title":"J Assist Reprod Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc1524","article-title":"Integrin-linked kinase: a cancer therapeutic target unique among its ILK","volume":"5","author":"Hannigan","year":"2005","journal-title":"Nat Rev Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e99322","DOI":"10.15252\/embj.201899322","article-title":"Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth","volume":"38","author":"Urner","year":"2019","journal-title":"EMBO J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0035-1552582","article-title":"The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome","volume":"33","author":"Tal","year":"2015","journal-title":"Semin Reprod Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13048-017-0308-5","article-title":"The role of Notch signalling in ovarian angiogenesis","volume":"10","author":"Xie","year":"2017","journal-title":"J Ovarian Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.mvr.2007.06.006","article-title":"Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells","volume":"75","author":"Harrington","year":"2008","journal-title":"Microvasc Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Hum Reprod Update."},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.repbio.2019.03.005","article-title":"Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): a potentially safer and more effective protocol","volume":"19","author":"Gaafar","year":"2019","journal-title":"Reprod Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1933719107310707","article-title":"Gonadotropin-releasing hormone in the ovary","volume":"14","author":"Metallinou","year":"2007","journal-title":"Reprod Sci."}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.704153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:05:58Z","timestamp":1625547958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.704153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":40,"alternative-id":["10.3389\/frph.2021.704153"],"URL":"https:\/\/doi.org\/10.3389\/frph.2021.704153","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"article-number":"704153"}}